I see your point, the FDA pimp slapped us several times.
I see your point, the FDA pimp slapped us several times. They are doing their best to use our drugs efficacy against us. It is like being stuck in the mud where you can go forward a little, and reverse a little, but the more you do it the deeper you dig the hole and they more costly it can be to get pulled out (more toxic loans and share dilution to the point a BP snatches us up cheap)
I disagree that this is the end for us with covid, I think it is time to focus our efforts on the longhaulers. We have months of data from people in our trials and from people receiving LL pre and post cd-12 trials as to their current conditions, don't we? Those that survived, how many are now considered long haulers? Would a third shot or a fourth shot decrease the number even more? We need to take whatever info we can gather and laser focus on long haulers. Let BP go after severe and critical, that is who the FDA is buying time for anyway with the nonsense BS they are pulling on us.
Maybe we should tell the Fda to kiss our ass on critical, stop wasting time and resources, and focus on longhaulers only. We need to make sure we have good endpoints for that trial and learned every lesson we can from our most recent trials (cd-10 and 12).
Once we get approval for longhaulers can't doctors start using it for severe/critical?
Pfizer sold their vaccine at a premium to Israel and included the results on the Israelis in their studies. what if we sold LL at a discount to Brazil or Phillipines and used the results from the critical patients they save as more proof that it works??? Won't the world be watching??? Wont the Fda look dumb as shit at that point???
Why play the FDA's game? Fck those A******* They are just buying time for BP buddies to come up with some half ass drug that they claim is wonderful. First to market means a lot, so we need to be more creative and use alternate channels. Doesnt the new 2 trillion covid relief bill create billions more $$$ in free money for BP, only this time instead of vaccines it is for therapeutics???
We do have options for covid, it just is not the conventional route afforded to BP. I say flip the script on the FDA and go full steam ahead at longhaulers.
In the meantime find a country that is not afraid of bullying from the US as a repercussion if they purchase LL before the FDA approves it in the US, and let's help the sick in their country... Hell, the way things are going in the U.S. I might just move to whatever country that is. At least they proved they care about their citizens health
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...
Continue Reading
The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...
Continue Reading
Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...
Continue Reading
A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...
Continue Reading
Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...
Continue Reading
Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...
Continue Reading
Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...
Continue Reading
NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...
Continue Reading
Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...
Continue Reading
Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...
Continue Reading
Top 5 Most Recently Viewed Articles
Oasis Management Advocates for Enhanced Governance at Kobayashi Pharma Oasis Management Company Ltd. (“Oasis”) has emerged as a significant voice among shareholders of Kobayashi Pharmaceutical Co., Ltd. (4967 JT). Holding over 7.5% of the company, Oasis is actively pushing for essential changes in leadership and independent oversight to address pressing governance...
Continue Reading
Understanding the Recent Class Action Lawsuit Against Synopsys Recently, concerns have emerged regarding Synopsys, Inc. as a class action lawsuit was filed alleging serious misrepresentations concerning the company’s financial health. Investors who have been affected are encouraged to seek guidance to explore their legal rights and options that may arise from this...
Continue Reading
Thrilling NCAA Basketball Coverage by Cumulus Media Cumulus Media’s Westwood One is gearing up for an exciting audio experience during the 2025 NCAA Men’s and Women’s Basketball tournaments. With the largest radio network in the country, Westwood One will deliver comprehensive coverage that connects die-hard sports fans across a plethora of platforms. Connecting...
Continue Reading
ByteDance's Strategic Investment in AI Technology ByteDance, the renowned owner of TikTok, is making significant strides in artificial intelligence by planning to invest more than $12 billion on AI infrastructure in the upcoming years. This ambitious investment highlights the company's commitment to harnessing cutting-edge technology for growth. According to reports, the...
Continue Reading
Investors of ModivCare, Inc. Urged to Join Class Action Lawsuit The law firm Robbins Geller Rudman & Dowd LLP is calling for investors of ModivCare, Inc. (NASDAQ: MODV) who have experienced significant financial losses to take action. Understanding the Class Action Lawsuit The upcoming class action lawsuit, titled Kalera v. ModivCare, Inc., brings serious allegations...
Continue Reading